NeuPath Health reduces loss in Q4 2023 while increasing revenues
Adjusted EBITDA attributable to shareholders of NeuPath Health for the quarter was C$0.8m, compared with C$0.7 a year ago.
Adjusted EBITDA attributable to shareholders of NeuPath Health for the quarter was C$0.8m, compared with C$0.7 a year ago.